Abstract
The incidence of diabetes is gradually increasing in China, and diabetes and associated complications, such as cognitive dysfunction have gained much attention in recent time. However, the concepts, clinical treatment, and prevention of cognitive dysfunction in patients with diabetes remain unclear. The Chinese Society of Endocrinology investigated the current national and overseas situation of cognitive dysfunction associated with diabetes. Based on research both in China and other countries worldwide, the Expert Consensus on Cognitive Dysfunction in Diabetes was established to guide physicians in the comprehensive standardized management of cognitive dysfunction in diabetes and to improve clinical outcomes in Chinese patients. This consensus presents an overview, definition and classification, epidemiology and pathogenesis, risk factors, screening, diagnosis, differential diagnosis, treatment, and prevention of cognitive dysfunction in patients with diabetes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. Jama, 2013,310(9):948–959
Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol, 2006,5(1):64–74
Reske-Nielsen E, Lundbæk K, Rafaelsen OJ. Pathological changes in the central and peripheral nervous system of young long-term diabetics: I. Diabetic encephalopathy. Diabetologia, 1966,1(3–4):233–241
Feinkohl I, Keller M, Robertson CM, et al. Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care, 2013,36(9):2779–2786
Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 1999,53(9):1937–1942
Cheng G, Huang C, Deng H, et al. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J, 2012,42(5):484–491
Barbiellini Amidei C, Fayosse A, Dumurgier J, et al. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. Jama, 2021,325(16):1640–1649
Yu JT, Xu W, Tan CC, et al. Evidence-based prevention of Alzheimer’s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry, 2020,91(11):1201–1209
Association AD. 12. Older adults: Standards of Medical Care in Diabetes. Diabetes Care, 2021,44(Suppl.1): S168–S179
Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol, 2018,14(10):591–604
Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol, 2014,10(11):634–42
Chinese guidelines for diagnosis and management of cognitive impairment and dementia (I): dementia subtypes and their criteria. Zhonghua Yi Xue Za Zhi (Chinese), 2018,98(13):965–970
2015 W A s R. Global Impact of Dementia. Medscape. August 27, 2015.
Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology, 2004,63(10):1902–1907
Srikanth V, Sinclair AJ, Hill-Briggs F, et al. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol, 2020,8(6):535–545
Koekkoek PS, Rutten GE, and Biessels GJ. Cognitive disorders in diabetic patients. Handb Clin Neurol, 2014, 126:145–166
Zhang Z, Bi Y. Pay attention to the early evaluation and diagnosis for cognitive decline in type 2 diabetes. Chin J Endocrinol Metab (Chinese), 2019,35(9):731–735
Exalto LG, Biessels GJ, Karter AJ, et al. Severe diabetic retinal disease and dementia risk in type 2 diabetes. J Alzheimers Dis, 2014,42 Suppl 3(0 3):S109–117
Zhang J, Chen C, Hua S, et al. An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract, 2017,124:41–47
Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care, 2009,32(2): 221–226
Ding J, Strachan MW, Reynolds RM, et al. Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes, 2010,59(11):2883–2889
Xu W, Caracciolo B, Wang HX, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes, 2010,59(11):2928–2935
Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. Jama, 2014,312(23):2551–2561
Hansson O, Lehmann S, Otto M, et al. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimers Res Ther, 2019,11(1):34
Sutphen CL, Jasielec MS, Shah AR, et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol, 2015,72(9):1029–1042
Wang L, Benzinger TL, Hassenstab J, et al. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease. Neurology, 2015,84(12): 1254–1260
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol, 2016,15(7):673–684
Mattson MP, Arumugam TV. Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. Cell Metab, 2018,27(6):1176–1199
Lou G, Palikaras K, Lautrup S, et al. Mitophagy and Neuroprotection. Trends Mol Med, 2020,26(1):8–20
Chinese guidelines for diagnosis and management of cognitive impairment and dementia (VII): risk factors and intervention in Alzheimer’s Disease. Zhonghua Yi Xue Za Zhi (Chinese), 2018,98(19):1461–1466
Kivipelto M, Mangialasche F, and Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol, 2018,14(11): 653–666
Xue M, Xu W, Ou YN, et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev, 2019,55:100944
Stoeckel LE, Arvanitakis Z, Gandy S, et al. Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. F1000Res, 2016,5:353
Su F, Shu H, Ye Q, et al. Brain insulin resistance deteriorates cognition by altering the topological features of brain networks. Neuroimage Clin, 2017,13:280–287
Denver P, McClean PL. Distinguishing normal brain aging from the development of Alzheimer’s disease: inflammation, insulin signaling and cognition. Neural Regen Res, 2018,13(10):1719–1730
Frolich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm (Vienna), 1998, 105(4–5):423–438
Jiménez-Palomares M, Ramos-Rodríguez JJ, López-Acosta JF, et al. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab, 2012,302(11):E1373–80
Gasparini L, Gouras GK, Wang R, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci, 2001,21(8):2561–2570
Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med, 2013,369(6):540–548
Valente T, Gella A, Fernàndez-Busquets X, et al. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis, 2010,37(1):67–76
Yuan XY, Wang XG. Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review. Rev Neurosci, 2017,28(7):715–723
Huang R, Tian S, Zhang H, et al. Chronic hyperglycemia induces tau hyperphosphorylation by downregulating OGT-involved O-GlcNAcylation in vivo and in vitro. Brain Res Bull, 2020,156:76–85
Malone JI, Hanna S, Saporta S, et al. Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory. Pediatr Diabetes, 2008,9(6):531–539
Smith L, Chakraborty D, Bhattacharya P, et al. Exposure to hypoglycemia and risk of stroke. Ann N Y Acad Sci, 2018,1431(1):25–34
Lee AK, Warren B, Lee CJ, et al. The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes. Diabetes Care, 2018,41(1):104–111
Feinkohl I, Aung PP, Keller M, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care, 2014,37(2):507–515
Lee AK, Rawlings AM, Lee CJ, et al. Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. Diabetologia, 2018,61(9):1956–1965
Crosby-Nwaobi R, Sivaprasad S, Forbes A. A systematic review of the association of diabetic retinopathy and cognitive impairment in people with Type 2 diabetes. Diabetes Res Clin Pract, 2012,96(2):101–110
Li J, Pan J, Li B, et al. Positive correlation between cognitive impairment and renal microangiopathy in patients with type 2 diabetic nephropathy: a multicenter retrospective study. J Int Med Res, 2018,46(12):5040–5051
Mehrabian S, Raycheva M, Gateva A, et al. Cognitive dysfunction profile and arterial stiffness in type 2 diabetes. J Neurol Sci, 2012,322(1–2):152–156
Petrova M, Prokopenko S, Pronina E, et al. Diabetes type 2, hypertension and cognitive dysfunction in middle age women. J Neurol Sci, 2010,299(1–2):39–41
Umegaki H, Iimuro S, Shinozaki T, et al. Risk factors associated with cognitive decline in the elderly with type 2 diabetes: pooled logistic analysis of a 6-year observation in the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int, 2012,12 Suppl 1:110–116
de Luis DA, Fernandez N, Arranz M, et al. Total homocysteine and cognitive deterioration in people with type 2 diabetes. Diabetes Res Clin Pract, 2002,55(3): 185–190
Lopez OL, Jagust WJ, Dulberg C, et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol, 2003, 60(10):1394–1399
12. Older Adults: Standards of Medical Care in Diabetes-2020. Diabetes Care, 2020,43(Suppl 1):S152-S162
Zhang Z, Zhang B, Wang X, et al. Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. Diabetes Care, 2019,42(7):1274–1283
Geijselaers SLC, Sep SJS, Stehouwer CDA, et al. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol, 2015,3(1):75–89
Moyer VA. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2014, 160(11):791–797
O’Driscoll C, Shaikh M. Cross-Cultural Applicability of the Montreal Cognitive Assessment (MoCA): A Systematic Review. J Alzheimers Dis, 2017,58(3):789–801
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 1993,43(11):2412–4
Zhou Y, Guo QH, Hong Z. Cognitive Abilities Screening Instrument—Chinese Revised Version in Participants with Mild Cognitive Impairment and Alzheimer’s Disease. Chin J Clin Neurosci (Chinese), 2009,17(1):49–53
Wang XX, Luo H. Application of several cognitive assessment scales in screening for Alzheimer’s disease. Chin J Clin Rational Drug Use (Chinese), 2015,8(6):173–174
Jia JP, Chen SD. Neurology. 7th edition. Beijing: People’s Medical Publishing House, 2013:123–124.
Cui R, Liu M. Hippocampus Analysis by Combination of 3-D DenseNet and Shapes for Alzheimer’s Disease Diagnosis. IEEE J Biomed Health Inform, 2019,23(5):2099–2107
Jagust W, Thisted R, Devous MD, Sr., et al. SPECT perfusion imaging in the diagnosis of Alzheimer’s disease: a clinical-pathologic study. Neurology, 2001, 56(7):950–956
Bohnen NI, Djang DS, Herholz K, et al. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med, 2012,53(1):59–71
Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology, 2008,71(10):743–9
Chinese guidelines for diagnosis and management of cognitive impairment and dementia (IV): auxiliary examination in cognitive disorders. Zhonghua Yi Xue Za Zhi (Chinese), 2018,98(15):1130–1142
Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol, 2003,2(10):605–613
Ritchie C, Smailagic N, Noel-Storr AH, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev, 2014,2014(6):Cd008782
Lewczuk P, Lelental N, Spitzer P, et al. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer’s disease: validation of two novel assays. J Alzheimers Dis, 2015,43(1):183–191
Pritchard SM, Dolan PJ, Vitkus A, et al. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. J Cell Mol Med, 2011,15(8):1621–1635
Portelius E, Westman-Brinkmalm A, Zetterberg H, et al. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res, 2006,5(4):1010–6
Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis, 2009,18(2):413–417
Grossman M, Farmer J, Leight S, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol, 2005,57(5):721–729
Schönknecht P, Pantel J, Hunt A, et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer’s disease. Neurosci Lett, 2003,339(2):172–174
Moran C, Beare R, Phan TG, et al. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology, 2015,85(13):1123–1130
Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med, 2020,26(3):379–386
Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol, 2020,19(5):422–433
Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. Jama, 2020,324(8):772–781
Jia L, Qiu Q, Zhang H, et al. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement, 2019,15(8):1071–1080
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 1984,34(7):939–944
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 2011,7(3):263–269
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol, 2014,13(6):614–629
Chinese cognitive impairment and dementia (II): guidelines for diagnosis and management of Alzhimer’s Disease. Zhonghua Yi Xue Za Zhi (Chinese), 2018, 98(13):971–977
Erickson KI, Hillman C, Stillman CM, et al. Physical Activity, Cognition, and Brain Outcomes: A Review of the 2018 Physical Activity Guidelines. Med Sci Sports Exerc, 2019,51(6):1242–1251
Crowe M, Andel R, Pedersen NL, et al. Does participation in leisure activities lead to reduced risk of Alzheimer’s disease? A prospective study of Swedish twins. J Gerontol B Psychol Sci Soc Sci, 2003,58(5):P249–255
Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry, 2013,84(12):1318–1325
Lehtisalo J, Levälahti E, Lindström J, et al. Dietary changes and cognition over 2 years within a multidomain intervention trial-The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimers Dement, 2019,15(3):410–417
Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial. JAMA Intern Med, 2015,175(7):1094–1103
Sofi F, Valecchi D, Bacci D, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med, 2011,269(1):107–117
Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med, 2009,39(1):3–11
Abbott RD, White LR, Ross GW, et al. Walking and dementia in physically capable elderly men. Jama, 2004,292(12):1447–1453
Tranah GJ, Blackwell T, Stone KL, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol, 2011,70(5):722–732
Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. Jama, 2008,299(22):2642–55
Forbes D, Blake CM, Thiessen EJ, et al. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. Cochrane Database Syst Rev, 2014,(2):Cd003946
Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol, 2011,10(11):969–977
Tang X, Cardoso MA, Yang J, et al. Impact of Intensive Glucose Control on Brain Health: Meta-Analysis of Cumulative Data from 16,584 Patients with Type 2 Diabetes Mellitus. Diabetes Ther, 2021,12(3):765–779
de Galan BE, Zoungas S, Chalmers J, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2009,52(11):2328–2336
Hsu CC, Wahlqvist ML, Lee MS, et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis, 2011,24(3):485–493
Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer’s disease. Ageing Res Rev, 2019,54:100936
Chin-Hsiao T. Metformin and the Risk of Dementia in Type 2 Diabetes Patients. Aging Dis, 2019,10(1):37–48
Ryan CM, Freed MI, Rood JA, et al. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care, 2006,29(2):345–351
Porter KM, Ward M, Hughes CF, et al. Hyperglycemia and Metformin Use Are Associated With B Vitamin Deficiency and Cognitive Dysfunction in Older Adults. J Clin Endocrinol Metab, 2019,104(10):4837–4847
Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging, 2011,32(9):1626–33
Cheng H, Shang Y, Jiang L, et al. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: a meta-analysis. Int J Neurosci, 2016,126(4):299–307
Cao B, Rosenblat JD, Brietzke E, et al. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer’s disease and mild cognitive impairment: A systematic review and network meta-analysis. Diabetes Obes Metab, 2018,20(10):2467–2471
Imfeld P, Bodmer M, Jick SS, et al. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc, 2012,60(5):916–921
Seaquist ER, Miller ME, Fonseca V, et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. J Diabetes Complications, 2013, 27(5):485–491
Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci, 2016,8:108
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol, 2020,19(7):582–590
Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol, 2014,13:148
Craft S, Raman R, Chow TW, et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol, 2020,77(9):1099–1109
Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ, 2019,367:l6217
Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 2000,54(12):2269–2276
Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia, 1996,7(6):293–303
Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med, 1998,158(9):1021–1031
Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet, 2002,359(9314): 1283–1290
Qaseem A, Snow V, Cross JT, Jr., et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008,148(5):370–378
Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standarddose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, doubleblind study. Clin Ther, 2010,32(7):1234–1251
Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease. Expert Opin Drug Deliv, 2008,5(12):1377–1386
Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama, 2004,291(3):317–324
Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry, 2009,24(5):532–538
Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer’s disease. J Alzheimers Dis, 2013,36(3):445–458
Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord, 2007,24(2):138–145
Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer’s disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord, 2014,37(1–2):71–85
Acknowledgements
The authors thank all the experts who participated in discussions and helped develop this consensus.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Author Xue-feng YU is a member of the Editorial Board for Current Medical Science. The paper was handled by the other editor and has undergone rigorous peer review process. Author Xue-feng YU was not involved in the journal’s review of, or decision related to, this manuscript.
Additional information
Yan YANG, Jia-jun ZHAO, Xue-feng YU, on behalf of the Neuroendocrinology Group, the Chinese Society of Endocrinology, Chinese Medical Association. The Chinese version of the article entitled “Expert Consensus on Cognitive Dysfunction in Diabetes” was initially published in Chinese Journal of Diabetes Mellitus (Chinese): 2021,13(7):678–694. DOI: https://doi.org/10.3760/cma.j.cn11579120210527-00291.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yang, Y., Zhao, Jj. & Yu, Xf. Expert Consensus on Cognitive Dysfunction in Diabetes. CURR MED SCI 42, 286–303 (2022). https://doi.org/10.1007/s11596-022-2549-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-022-2549-9